CA3069423C — Formulations for the treatment of fungal infections
Assigned to NAPP PHARMACEUTICAL GROUP Ltd · Expires 2025-04-15 · 1y expired
What this patent protects
The invention relates to non-irritating pharmaceutical compositions containing CD101 in a pharmaceutically acceptable salt (e.g., CD101 acetate) or a neutral form. These pharmaceutical compositions can be administered intravenously to a subject to treat fungal infections (e.g., c…
USPTO Abstract
The invention relates to non-irritating pharmaceutical compositions containing CD101 in a pharmaceutically acceptable salt (e.g., CD101 acetate) or a neutral form. These pharmaceutical compositions can be administered intravenously to a subject to treat fungal infections (e.g., candidiasis) in that subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.